CHARLES RIVER LABORATORIES INTERNATIONAL, INC. acquired SAMDI Tech, Inc. for $62.8 million (net of $0.4 million cash, inclusive of a previously owned 20% interest valued at $12.6 million), a transaction completed in January 2023, structured as cash.
SAMDI Tech, Inc. operates in DSA. Charles River Laboratories acquired SAMDI Tech, Inc. on January 27, 2023, capping an exclusive partnership between the two companies that began in 2018. SAMDI supplies label-free, high-throughput screening solutions for drug discovery, and the roughly $62.8 million purchase gave Charles River clients direct access to its label-free HTS mass spectrometry platform as part of a broader library of discovery capabilities. The business was folded into Charles River's Discovery and Safety Assessment (DSA) reporting segment.
Added a label-free HTS MS drug-discovery platform to Charles River's DSA solutions portfolio.
Advisory firms were not disclosed for this transaction.